Kazazian Asset Management LLC boosted its position in shares of Isotechnika Pharma Inc. (NASDAQ:AUPH) (TSE:AUP) by 11.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 156,126 shares of the biotechnology company’s stock after purchasing an additional 16,189 shares during the period. Kazazian Asset Management LLC owned 0.19% of Isotechnika Pharma worth $707,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AUPH. Goldman Sachs Group Inc. lifted its position in shares of Isotechnika Pharma by 36.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,194,550 shares of the biotechnology company’s stock worth $5,411,000 after buying an additional 319,639 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Isotechnika Pharma by 33.2% during the 4th quarter. Franklin Resources Inc. now owns 1,664,400 shares of the biotechnology company’s stock worth $7,540,000 after purchasing an additional 414,400 shares during the last quarter. Hudson Bay Capital Management LP lifted its position in shares of Isotechnika Pharma by 20.0% during the 4th quarter. Hudson Bay Capital Management LP now owns 450,000 shares of the biotechnology company’s stock worth $2,039,000 after purchasing an additional 75,000 shares during the last quarter. Spark Investment Management LLC acquired a new position in shares of Isotechnika Pharma during the 4th quarter worth about $153,000. Finally, BlackRock Inc. acquired a new position in shares of Isotechnika Pharma during the 4th quarter worth about $3,261,000. 28.50% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently issued reports on the company. BidaskClub upgraded Isotechnika Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, January 25th. Seaport Global Securities reiterated a “buy” rating and issued a $11.00 price objective on shares of Isotechnika Pharma in a research note on Friday, March 16th. Zacks Investment Research upgraded Isotechnika Pharma from a “strong sell” rating to a “hold” rating in a research note on Monday, January 22nd. Finally, Cantor Fitzgerald set a $16.00 price objective on Isotechnika Pharma and gave the company an “overweight” rating in a research note on Thursday, March 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $10.93.
Shares of AUPH stock traded down $0.05 during trading hours on Friday, reaching $5.15. The company had a trading volume of 423,534 shares, compared to its average volume of 714,988. The company has a market cap of $437.07, a P/E ratio of -5.60 and a beta of 2.26. Isotechnika Pharma Inc. has a 1-year low of $4.41 and a 1-year high of $8.19.
Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.10. Isotechnika Pharma had a negative net margin of 16,855.24% and a negative return on equity of 17.54%. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter in the prior year, the company earned ($0.11) EPS. The firm’s quarterly revenue was up .0% on a year-over-year basis. analysts predict that Isotechnika Pharma Inc. will post -0.7 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Kazazian Asset Management LLC Has $707,000 Stake in Isotechnika Pharma Inc. (AUPH)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/kazazian-asset-management-llc-purchases-16189-shares-of-aurinia-pharmaceuticals-inc-auph.html.
About Isotechnika Pharma
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.
Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.